Chemotherapy and Radiation Following Pancreatic Surgery

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.

To describe the toxicities associated with adjuvant chemoradiation with cisplatin. 5FU and interferon alfa followed by gemcitabine in patients with pancreatic cancers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Cisplatin; Fluorouracil; Gemcitabine; Interferon-alfa-1b; Interferon-alpha; Interferons

Criteria

• Resected adenocarcinoma of the pancreas

• ECOG performance status 0 or 1

• No prior chemotherapy or radiation therapy for cancer within the last five years.

• Prior history of other malignancies allowable, if stable or requiring no active therapy.

• Absolute neutrophil count >/= 1,500/mm3, platelet count >/= 100,000/mm3, and hemoglobin >/= 9 g/dL.

• Serum creatinine
• Serum bilirubin
• Serum transaminases ( SGOT and SGPT)
• No co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection.

• Able to sign an informed consent.